Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 19:14:1380716.
doi: 10.3389/fonc.2024.1380716. eCollection 2024.

A systematic review and meta-analysis of radiotherapy and particle beam therapy for skull base chondrosarcoma: TRP-chondrosarcoma 2024

Masatoshi Nakamura  1 , Masashi Mizumoto  1 , Takashi Saito  1 , Shosei Shimizu  2 , Yinuo Li  1 , Yoshiko Oshiro  1   3 , Masako Inaba  4 , Sho Hosaka  4 , Hiroko Fukushima  5 , Ryoko Suzuki  5 , Takashi Iizumi  1 , Kei Nakai  1 , Kazushi Maruo  6 , Hideyuki Sakurai  1
Affiliations

A systematic review and meta-analysis of radiotherapy and particle beam therapy for skull base chondrosarcoma: TRP-chondrosarcoma 2024

Masatoshi Nakamura et al. Front Oncol. .

Abstract

Introduction: Chondrosarcoma is a rare malignant bone tumor. Particle beam therapy (PT) can concentrate doses to targets while reducing adverse events. A meta-analysis based on a literature review was performed to examine the efficacy of PT and photon radiotherapy for skull base chondrosarcoma.

Methods: The meta-analysis was conducted using 21 articles published from 1990 to 2022.

Results: After PT, the 3- and 5-year overall survival (OS) rates were 94.1% (95% confidence interval [CI]: 91.0-96.2%) and 93.9% (95% CI: 90.6-96.1%), respectively, and the 3- and 5-year local control rates were 95.4% (95% CI: 92.0-97.4%) and 90.1% (95% CI: 76.8-96.0%), respectively. Meta-regression analysis revealed a significant association of PT with a superior 5-year OS rate compared to three-dimensional conformal radiotherapy (p < 0.001). In the studies used in the meta-analysis, the major adverse event of grade 2 or higher was temporal lobe necrosis (incidence 1-18%, median 7%).

Conclusion: PT for skull base chondrosarcoma had a good outcome and may be a valuable option among radiotherapy modalities. However, high-dose postoperative irradiation of skull base chondrosarcoma can cause adverse events such as temporal lobe necrosis.

Keywords: TRP; chondrosarcoma; meta-analysis; proton; skull base; systematic review; temporal lobe necrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Process for selection of articles.
Figure 2
Figure 2
Forest plots for (A) 3-year and (B) 5-year overall survival rates after particle beam therapy.
Figure 3
Figure 3
Forest plots for (A) 3-year and (B) 5-year local control rates after particle beam therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gazendam A, Popovic S, Parasu N, Ghert M. Chondrosarcoma: a clinical review. J Clin Med. (2023) 12:2506. doi: 10.3390/jcm12072506 - DOI - PMC - PubMed
    1. Awad M, Gogos AJ, Kaye AH. Skull base chondrosarcoma. J Clin Neurosci. (2016) 24:1–5. doi: 10.1016/j.jocn.2015.10.029 - DOI - PubMed
    1. Kremenevski N, Schlaffer SM, Coras R, Kinfe TM, Graillon T, Buchfelder M. Skull base chordomas and chondrosarcomas. Neuroendocrinology. (2020) 110:836–47. doi: 10.1159/000509386 - DOI - PubMed
    1. Patel S, Nunna RS, Ryoo JS, Ansari D, Chaudhry NS, Mehta AI. Outcomes and patterns of care in adult skull base chondrosarcoma patients in the United States. World Neurosurg. (2021) 150:71–83. doi: 10.1016/j.wneu.2021.03.097 - DOI - PubMed
    1. Combs SE, Baumert BG, Bendszus M, Bozzao A, Brada M, Fariselli L, et al. . ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiother Oncol. (2021) 156:80–94. doi: 10.1016/j.radonc.2020.11.014 - DOI - PubMed

Publication types

LinkOut - more resources